Selenium Sulfide
CAS 7488-56-4
Selenium Sulfide (CAS 7488-56-4) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 195 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Selenium sulfide | 36345 | SU | MTHSPL |
| SELENIUM SULFIDE | 36345 | SU | MTHSPL |
| Selenium Sulfide | 36345 | SU | MTHSPL |
| selenium sulfide | 36345 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Selenium Sulfide used for in pharmaceutical contexts?
Selenium Sulfide (CAS 7488-56-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Selenium Sulfide?
Selenium Sulfide has 195 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Accidental exposure to product, Adverse drug reaction, Anxiety, Aspiration, Asthenia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Selenium Sulfide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Selenium Sulfide with EU status "prohibited".
What clinical phase is Selenium Sulfide in?
Selenium Sulfide is rendered with ChEMBL max phase 4 (approved).